Laurus Labs Limited has informed the Exchange regarding 'Business Responsibility and Sustainability Reporting (BRSR)'.
LAURUSLABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Laurus Labs has submitted its annual BRSR filing for FY 2024-25 as mandated by SEBI's listing regulations. The pharma company reported a turnover of INR 5,217 crores and net worth of INR 4,564 crores, with exports contributing 65.33% of revenue across 105 countries. The company employs 6,167 permanent staff (92% male, 8% female) plus 6,300 contract workers across 9 plants in Visakhapatnam and Hyderabad. Key highlights include zero safety incidents, zero regulatory penalties or fines, and zero stakeholder complaints across all NGRBC principles. The report, assured by Deloitte Haskins & Sells LLP on a limited basis, flagged material risks around EHS, regulatory compliance, competition, innovation, and forex fluctuations. Women representation on the board stands at 20% (2 of 10 directors), and the company maintains ISO 45001 and ISO 14001 certifications.
This is a routine annual ESG/sustainability disclosure required by SEBI and is unlikely to materially move the stock price. However, it signals a clean compliance record, no significant safety or governance issues, and improving employee stability (turnover down to 17% from 19%), which may appeal to ESG-focused institutional investors.